Pharmaceutical companies and healthcare providers

Going beyond the gift. An explorative review

Tom Latten, Daan Westra, Federica Angeli, Aggie Paulus, Marleen Struss, Dirk Ruwaard

Research output: Contribution to journalArticleScientificpeer-review

1 Downloads (Pure)

Abstract

Introduction: 

Interactions between pharmaceutical companies and healthcare providers are increasingly scrutinized by academics, professionals, media, and politicians. Most empirical studies and professional guidelines focus on unilateral donor-recipient types of interaction and overlook, or fail to distinguish between, more reciprocal types of interaction. However, the degree of goal alignment and potential for value creation differs in these two types of interactions. Failing to differentiate between these two forms of interaction between pharmaceutical companies and healthcare providers could thus lead to biased conclusions regarding their desirability. This study reviews the empirical literature regarding the effects of bilateral forms of interactions between pharmaceutical companies and healthcare providers in order to explore their effects.

Material and methods: 

We searched two medical databases (i.e. PubMed and Cochrane Library) and one business database (i.e. EBSCO) for empirical, peer-reviewed articles concerning any type of bilateral interaction between pharmaceutical companies and healthcare providers. We included quantitative articles which were written in English and published between January 1st, 2000 and October 31st, 2016, and where the title or abstract included a combination of synonyms of the following keywords: pharmaceutical companies, healthcare providers, interaction, and effects.

Results: 

Our search results yielded 10 studies which were included in our analysis. These studies focused on either research-oriented interaction or on education-oriented interaction. The included studies reported various outcomes of interaction such as prescribing behavior, ethical dilemmas, and research output. Regardless of the type of interaction, the studies either reported no significant effects or ambivalent outcomes such as affected clinical practice or ethical issues.

Discussion and conclusion: 

The effects of bilateral interactions reported in the literature are similar to those reported in studies concerning unilateral interactions. The theoretical notion that bilateral interactions between pharmaceutical companies and healthcare providers have different effects given their increased level of goal alignment thus does not seem to hold. However, most of the empirical studies focus on intermediary, provider-level, outcomes such as altered prescribing behavior. Outcomes at the health system level such as overall costs and quality of care are overlooked. Further research is necessary in order to disentangle various forms of value created by different types of interactions between pharmaceutical companies and healthcare providers.

Original languageEnglish
Article numbere0191856
Number of pages15
JournalPLoS ONE
Volume13
Issue number2
DOIs
Publication statusPublished - 2018

Fingerprint

Health Personnel
Pharmaceutical Preparations
Industry
Databases
PubMed
Ethics
Libraries
Education
Health
Costs

Keywords

  • CONFLICTS-OF-INTEREST
  • PHYSICIAN PRESCRIBING PATTERNS
  • DRUG COMPANIES
  • INTERORGANIZATIONAL RELATIONSHIPS
  • STRATEGIC NETWORKS
  • INDUSTRY PAYMENTS
  • GUIDELINES
  • IMPACT
  • DOCTORS
  • ETHICS

Cite this

Latten, T., Westra, D., Angeli, F., Paulus, A., Struss, M., & Ruwaard, D. (2018). Pharmaceutical companies and healthcare providers: Going beyond the gift. An explorative review. PLoS ONE, 13(2), [e0191856]. https://doi.org/10.1371/journal.pone.0191856
Latten, Tom ; Westra, Daan ; Angeli, Federica ; Paulus, Aggie ; Struss, Marleen ; Ruwaard, Dirk. / Pharmaceutical companies and healthcare providers : Going beyond the gift. An explorative review. In: PLoS ONE. 2018 ; Vol. 13, No. 2.
@article{3f440dc899c74f9eae095cfbbb0cbf8f,
title = "Pharmaceutical companies and healthcare providers: Going beyond the gift. An explorative review",
abstract = "Introduction: Interactions between pharmaceutical companies and healthcare providers are increasingly scrutinized by academics, professionals, media, and politicians. Most empirical studies and professional guidelines focus on unilateral donor-recipient types of interaction and overlook, or fail to distinguish between, more reciprocal types of interaction. However, the degree of goal alignment and potential for value creation differs in these two types of interactions. Failing to differentiate between these two forms of interaction between pharmaceutical companies and healthcare providers could thus lead to biased conclusions regarding their desirability. This study reviews the empirical literature regarding the effects of bilateral forms of interactions between pharmaceutical companies and healthcare providers in order to explore their effects.Material and methods: We searched two medical databases (i.e. PubMed and Cochrane Library) and one business database (i.e. EBSCO) for empirical, peer-reviewed articles concerning any type of bilateral interaction between pharmaceutical companies and healthcare providers. We included quantitative articles which were written in English and published between January 1st, 2000 and October 31st, 2016, and where the title or abstract included a combination of synonyms of the following keywords: pharmaceutical companies, healthcare providers, interaction, and effects.Results: Our search results yielded 10 studies which were included in our analysis. These studies focused on either research-oriented interaction or on education-oriented interaction. The included studies reported various outcomes of interaction such as prescribing behavior, ethical dilemmas, and research output. Regardless of the type of interaction, the studies either reported no significant effects or ambivalent outcomes such as affected clinical practice or ethical issues.Discussion and conclusion: The effects of bilateral interactions reported in the literature are similar to those reported in studies concerning unilateral interactions. The theoretical notion that bilateral interactions between pharmaceutical companies and healthcare providers have different effects given their increased level of goal alignment thus does not seem to hold. However, most of the empirical studies focus on intermediary, provider-level, outcomes such as altered prescribing behavior. Outcomes at the health system level such as overall costs and quality of care are overlooked. Further research is necessary in order to disentangle various forms of value created by different types of interactions between pharmaceutical companies and healthcare providers.",
keywords = "CONFLICTS-OF-INTEREST, PHYSICIAN PRESCRIBING PATTERNS, DRUG COMPANIES, INTERORGANIZATIONAL RELATIONSHIPS, STRATEGIC NETWORKS, INDUSTRY PAYMENTS, GUIDELINES, IMPACT, DOCTORS, ETHICS",
author = "Tom Latten and Daan Westra and Federica Angeli and Aggie Paulus and Marleen Struss and Dirk Ruwaard",
year = "2018",
doi = "10.1371/journal.pone.0191856",
language = "English",
volume = "13",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "PUBLIC LIBRARY SCIENCE",
number = "2",

}

Latten, T, Westra, D, Angeli, F, Paulus, A, Struss, M & Ruwaard, D 2018, 'Pharmaceutical companies and healthcare providers: Going beyond the gift. An explorative review', PLoS ONE, vol. 13, no. 2, e0191856. https://doi.org/10.1371/journal.pone.0191856

Pharmaceutical companies and healthcare providers : Going beyond the gift. An explorative review. / Latten, Tom; Westra, Daan; Angeli, Federica; Paulus, Aggie; Struss, Marleen; Ruwaard, Dirk.

In: PLoS ONE, Vol. 13, No. 2, e0191856, 2018.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Pharmaceutical companies and healthcare providers

T2 - Going beyond the gift. An explorative review

AU - Latten, Tom

AU - Westra, Daan

AU - Angeli, Federica

AU - Paulus, Aggie

AU - Struss, Marleen

AU - Ruwaard, Dirk

PY - 2018

Y1 - 2018

N2 - Introduction: Interactions between pharmaceutical companies and healthcare providers are increasingly scrutinized by academics, professionals, media, and politicians. Most empirical studies and professional guidelines focus on unilateral donor-recipient types of interaction and overlook, or fail to distinguish between, more reciprocal types of interaction. However, the degree of goal alignment and potential for value creation differs in these two types of interactions. Failing to differentiate between these two forms of interaction between pharmaceutical companies and healthcare providers could thus lead to biased conclusions regarding their desirability. This study reviews the empirical literature regarding the effects of bilateral forms of interactions between pharmaceutical companies and healthcare providers in order to explore their effects.Material and methods: We searched two medical databases (i.e. PubMed and Cochrane Library) and one business database (i.e. EBSCO) for empirical, peer-reviewed articles concerning any type of bilateral interaction between pharmaceutical companies and healthcare providers. We included quantitative articles which were written in English and published between January 1st, 2000 and October 31st, 2016, and where the title or abstract included a combination of synonyms of the following keywords: pharmaceutical companies, healthcare providers, interaction, and effects.Results: Our search results yielded 10 studies which were included in our analysis. These studies focused on either research-oriented interaction or on education-oriented interaction. The included studies reported various outcomes of interaction such as prescribing behavior, ethical dilemmas, and research output. Regardless of the type of interaction, the studies either reported no significant effects or ambivalent outcomes such as affected clinical practice or ethical issues.Discussion and conclusion: The effects of bilateral interactions reported in the literature are similar to those reported in studies concerning unilateral interactions. The theoretical notion that bilateral interactions between pharmaceutical companies and healthcare providers have different effects given their increased level of goal alignment thus does not seem to hold. However, most of the empirical studies focus on intermediary, provider-level, outcomes such as altered prescribing behavior. Outcomes at the health system level such as overall costs and quality of care are overlooked. Further research is necessary in order to disentangle various forms of value created by different types of interactions between pharmaceutical companies and healthcare providers.

AB - Introduction: Interactions between pharmaceutical companies and healthcare providers are increasingly scrutinized by academics, professionals, media, and politicians. Most empirical studies and professional guidelines focus on unilateral donor-recipient types of interaction and overlook, or fail to distinguish between, more reciprocal types of interaction. However, the degree of goal alignment and potential for value creation differs in these two types of interactions. Failing to differentiate between these two forms of interaction between pharmaceutical companies and healthcare providers could thus lead to biased conclusions regarding their desirability. This study reviews the empirical literature regarding the effects of bilateral forms of interactions between pharmaceutical companies and healthcare providers in order to explore their effects.Material and methods: We searched two medical databases (i.e. PubMed and Cochrane Library) and one business database (i.e. EBSCO) for empirical, peer-reviewed articles concerning any type of bilateral interaction between pharmaceutical companies and healthcare providers. We included quantitative articles which were written in English and published between January 1st, 2000 and October 31st, 2016, and where the title or abstract included a combination of synonyms of the following keywords: pharmaceutical companies, healthcare providers, interaction, and effects.Results: Our search results yielded 10 studies which were included in our analysis. These studies focused on either research-oriented interaction or on education-oriented interaction. The included studies reported various outcomes of interaction such as prescribing behavior, ethical dilemmas, and research output. Regardless of the type of interaction, the studies either reported no significant effects or ambivalent outcomes such as affected clinical practice or ethical issues.Discussion and conclusion: The effects of bilateral interactions reported in the literature are similar to those reported in studies concerning unilateral interactions. The theoretical notion that bilateral interactions between pharmaceutical companies and healthcare providers have different effects given their increased level of goal alignment thus does not seem to hold. However, most of the empirical studies focus on intermediary, provider-level, outcomes such as altered prescribing behavior. Outcomes at the health system level such as overall costs and quality of care are overlooked. Further research is necessary in order to disentangle various forms of value created by different types of interactions between pharmaceutical companies and healthcare providers.

KW - CONFLICTS-OF-INTEREST

KW - PHYSICIAN PRESCRIBING PATTERNS

KW - DRUG COMPANIES

KW - INTERORGANIZATIONAL RELATIONSHIPS

KW - STRATEGIC NETWORKS

KW - INDUSTRY PAYMENTS

KW - GUIDELINES

KW - IMPACT

KW - DOCTORS

KW - ETHICS

U2 - 10.1371/journal.pone.0191856

DO - 10.1371/journal.pone.0191856

M3 - Article

VL - 13

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 2

M1 - e0191856

ER -